Also, CXCL4/PF-4 has been proposed as a biomarker of early tumor growth in different tumors types, and appears to be up-regulated in human liposarcoma, mammary adenocarcinoma, osteosarcoma [7,34] and in other hematologic disorders [35]. Here, PF4 is linked to hematologic disorder.